At 6.9% CAGR, the North America Cardiac Microcatheter Market is projected to be worth US$ 188.10 million by 2028, says Business Market Insights

According to Business Market Insights research, the North America cardiac microcatheter market was valued at US$ 134.79 million in 2023 and is expected to reach US$ 188.10 million by 2028, registering a CAGR of 6.9% from 2023 to 2028. High prevalence of cardiovascular diseases and growing use of percutaneous coronary intervention (PCI) for treating chronic total occlusions (CTO) are the critical factors attributed to the North America cardiac microcatheter market expansion.

Percutaneous coronary intervention (PCI) is one of the most difficult procedures for treating of chronic total occlusions (CTO), resulting in successful recanalization of CTO. CTOPCIs represent 4% of all PCIs for stable angina in the US. Further, CTO is complete or near-complete blockage of one or more coronary arteries. The blockage usually lasts approximately three months due to plaque build-up within a coronary artery. As per the National Heart, Lung, and Blood Institute, CTOs are found in approximately one-third of patients undergoing angiography.  Significant progress has been made in this area over the past decade, given the novel product launches and approvals. However, the launch of new technical devices and strategic refinements are still being monitored in the procedures to combat CTOs as the microcatheters are used as a coronary interventional tool. This tool provides a therapeutic approach to complex coronary interventions such as bifurcation lesions, tortuous anatomy, ostial location, coronary calcification, angled takeoffs, and CTO. Terumo's FineCross MG microcatheter integrates cross ability and guidewire support for treating challenging cases including tortuous vessels, CTOs, bifurcations, as well as severely stenosed and calcified lesions. Therefore, the growing usage of PCIs for treating CTO is catalyzing the North America cardiac microcatheter market growth.

On the contrary, complications and failures related to usage of cardiac microcatheters hampers the North America Cardiac Microcatheter Market.  

Based on indication, the North America cardiac microcatheter market is segmented into general peripheral vascular and coronary. The coronary segment held 58.2% share of North America Cardiac Microcatheter Market in 2023, amassing US$ 78.41 million. It is projected to garner US$ 110.35 million by 2028 to expand at 7.1% CAGR during 2023–2028.

Based on end user, the North America cardiac microcatheter market is segmented into hospitals, specialty clinics, and ambulatory surgical centers. The hospitals segment held 44.7% share of North America Cardiac Microcatheter Market in 2023, amassing US$ 60.23 million. It is projected to garner US$ 85.39 million by 2028 to expand at 7.2% CAGR during 2023–2028.

Based on country, the North America cardiac microcatheter market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 78.6% share of North America Cardiac Microcatheter Market in 2023. It was assessed at US$ 105.95 million in 2023 and is likely to hit US$ 148.81 million by 2028, exhibiting a CAGR of 7.0% during the forecast period.      

Key players dominating the North America cardiac microcatheter market are Asahi Intecc USA Inc; Boston Scientific Corp; Integer Holdings Corp; Medtronic Plc; Merit Medical Systems Inc; Nipro Corp; Teleflex Inc; and Terumo Corp, among others.   

• In February 2022, Teleflex Incorporated, a leading global provider of medical technologies, announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded indication for its specialty catheters and coronary guidewires for use in crossing chronic total occlusion percutaneous coronary interventions (CTO PCI).
• In July 2021, Terumo Medical Corporation (TMC) announced AZUR Vascular Plug, the first and only plug compatible with a microcatheter to occlude arteries up to 8mm in diameter. The newest addition to Terumo's robust embolization portfolio is indicated for use to reduce or block the blood flow rate in peripheral vasculature arteries.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com